Pharmaceutical

BioNTech bolsters mRNA pipeline with $1.25bn CureVac acquisition

BioNTech has agreed to acquire CureVac for approximately $1.25bn, as the former amps up its strategy to offer cancer treatments.

Jun 13, 2025 - 06:00
BioNTech bolsters mRNA pipeline with $1.25bn CureVac acquisition
BioNTech has agreed to acquire CureVac for approximately $1.25bn, as the former amps up its strategy to offer cancer treatments.
Read the original article

Tags:

Previous Article

FDA approves label expansion of AbbVie hepatitis C therapy

Next Article

Wes Streeting: £29bn NHS boost ‘substantial’ but reform still needed

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Bright Health looks to get out of health insurance entirely

STAT+: Bright Health looks to get out of health insuran...

Apr 29, 2023

Listen: Vertex’s polarizing data, Aduhelm’s adieu, & an FDA icon

Listen: Vertex’s polarizing data, Aduhelm’s adieu, & an...

Feb 1, 2024

FDA approves Syndax’s Revuforj to treat leukaemia

FDA approves Syndax’s Revuforj to treat leukaemia

Nov 19, 2024